Current issues in phase I trials: New study designs and informed consent procedures

Annals of Oncology

Volumn 10, Issue SUPPL. 6, 1999, Pages

  Cavalli, Franco ^a   Sessa, C ^b  

^a OSPEDALE SAN GIOVANNI   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL PROTOCOL; CONFERENCE PAPER; DOSE RESPONSE; DRUG RESEARCH; DRUG SAFETY; HUMAN; INFORMED CONSENT; PATIENT SELECTION; PRIORITY JOURNAL;

EID: 0033375647     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/10.suppl_6.S147     Document Type: Conference Paper

References (17)

1. The European Agency for the Evaluation of Medicinal Products. "Note for guidance on evaluation of anticancer medicinal products in man." 1996.
2. Itoh K, Sasaki Y, Fujii H et al. Patients in phase I trials of anti-cancer agents in Japan: Motivations, comprehension and expectations. Br J Cancer 1997; 76: 107-13.
3. Daugherty C, Ratain M, Grochowski E et al. Perceptions of cancer patients and their physicians involved in Phase I trials. J Clin Oncol 1995; 13: 1062-72.
4. Decoster G, Stein G, Holdener E. Responses and toxic deaths in Phase I clinical trials. Ann Oncol 1990; 1: 175-81.
5. Arbuck S G. Workshop on phase 1 study design. Ann Oncol 1996; 7: 567-73.
6. Ratain M, Mick R, Schilsky R et al. Statistical and ethical issues in the design and conduct of Phase I and II clinical trials of new anticancer agents. J Natl Cancer Inst 1993; 85: 1637-43.
7. American Society of Clinical Oncology. Critical role of Phase I clinical trials in cancer treatment. J Clin Oncol 1997; 15: 853-9.
8. Simon R, Freidlin B, Rubinstein L et al. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 1997; 89: 1138-47.
9. O'Quigley J, Pepe M, Fischer L. Continual reassessment method: a practical design for Phase I clinical trials in cancer. Biometrics 1990; 46: 33-48.
10. Faries D. Practical modifications of the continual reassessment method for Phase I cancer clinical trials. J Biopharm Statistics 1994; 4: 147-64.
11. Siu L, Rowinsky E, Clark G et al. Dose escalation using the modified continual reassessment method (MCRM) in Phase I clinical trials: A review of the San Antonio experience. Ann Oncol 9 (Suppl 2): 127 (Abstr 487).
12. Lebecq A, Dieras V, Marty M et al. Preliminary evaluation of the modified continual reassessment method (MCRM) in four Phase I studies with RPR 109881A Ann Oncol 9 (Suppl 2): 127 (Abstr. 487).
13. Penman D, Holland J, Bahna G et al. Informed consent for investigational chemotherapy: Patients' and physicians' perceptions. J Clin Oncol 1984; 2: 849-55.
14. Tomamichel M, Sessa C, Herzig S et al. Informed consent for Phase I studies: Evaluation of quantity and quality of information provided to patients. Ann Oncol 1995; 6: 363-9.
15. Schaeffer M, Krautz D, Wichman A et al. The impact of disease severity on the informed consent process in clinical research. Am J Med 1996; 100: 261-8.
16. Daugherty C, Ratain M, Minami H et al. Study of cohort-specific consent and patient control in phase I cancer trials. J Clinic Oncol 1998; 16: 2305-12.
17. Sessa C and Cavalli F. Who benefits from phase I studies? Ann Oncol 1990; 1: 164-5.